Page 13

Radiology Life • February 2017

13 / ADVANCE FOR RADIOLOGY LiFE | CANCER THERAPY References 1. American Cancer Society (2016). Key statistics for thyroid cancer. Retrieved from http:// www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-key-statistics 2. Haugen BR, Alexander EK, Bible KC, et al. 2015. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer, Thyroid. Vol. 26, Number 1, 2016. 3. Hall FT, Beasley NJ, Eski SJ, et al. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope 113(1), 77–81 (2003). 4. Vaisman A, Orlov S, Yip J, et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in lowrisk papillary thyroid carcinoma. Head Neck. 32(6), 689–698 (2010). 5. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 90(3), 1440–1445 (2005). 6. Rosario PW, Xavier AC, Calsolari MR. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and (1)(3)(1)I activity in patients with thyroid cancer and low risk of recurrence. Thyroid. 21(1), 49–53 (2011). 7. Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease free remission and death in differentiated thyroid carcinoma. Clin Endocrinol. 66(1), 58–64 (2007). 8. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 37(2), 457–480, x (2008). 9. Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 89(8), 3668 3676 (2004). 10. Sacks W, Fung CH, Chang JT, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 20(11), 1235–1245 (2010). 11. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 19(11), 1167–1214 (2009). 12. Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol. 81(Suppl 1), 1–122 (2014). 13. Haymart MR, Banerjee M, Stewart AK, et al. Use of radioactive iodine for thyroid cancer. JAMA 306(7), 721–728 (2011). 14. Sawka AM, Goldstein DP, Thabane L, et al. Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey. Endocr Pract. 14(2), 175–184 (2008) 15. Nascimento C, Borget I, Al Ghuzlan A, et al. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer. 18(2), R29–R40 (2011). 16. Rosario PW, Mineiro AF, Prates BS, Silva LC, Calsolari MR. Postoperative stimulated Thyroglobulin less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioiodine ablation. Thyroid (2012). 17. Webb RC, Howard RS, Stojadinovic A, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 97(8),2754–2763 (2012). 18. Giovanella L, Treglia G, Sadeghi R, et al. Unstimulated highly sensitive thyroglobulin in follow up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab. 99(2), 440–447 (2014). 19. Orlov S, Salari F, Kashat L, et al. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer. Endocrine. 2015;50:130–7. The need to access new capital to invest in these technologies will likely be one of the largest drivers of radiology industry deals in the years to come.” Related Content For information on other progressive cancer therapies, read “Cancer Diagnosis in a Drop of Blood” at RadiologyLife. advanceweb.com FEBRUARY 2017


Radiology Life • February 2017
To see the actual publication please follow the link above